NasdaqGM:NRIXBiotechs
A Look At Nurix Therapeutics (NRIX) Valuation After New NX-5948 Data And EHA Congress Selection
Nurix Therapeutics (NRIX) is back in focus after reporting new preclinical and Phase 1 data for its BTK degrader NX-5948, and after securing an oral presentation slot at the European Hematology Association Congress.
See our latest analysis for Nurix Therapeutics.
Despite the recent NX-5948 data and the upcoming European Hematology Association presentation, Nurix Therapeutics’ share price has eased over the past month, with a 30 day share price return of 9.45% down, even as the 1 year total...